Increased Supply of RSV Infant Shots Coming to US Market
Originally Published 2 years ago — by Reuters
AstraZeneca and Sanofi, the makers of a respiratory syncytial virus (RSV) immunization for infants, will deliver an additional 230,000 doses in January to meet the high demand in the United States. This brings the total number of doses to be delivered this year to 1.4 million, exceeding the original plan by over 25%. The increased supply is a result of discussions between the companies and U.S. government officials. RSV is a leading cause of hospitalization among infants, and the expanded supply will allow the U.S. to provide the vaccine to 40% of the birth cohort this RSV season.